"目录号: HY-13733
Procarbazine盐酸盐为抗肿瘤烷化剂，可作用于霍奇金氏淋巴瘤和一些脑癌。
相关产品
Mitomycin C-Oxaliplatin-Temozolomide-Streptozocin-Carboplatin-Cyclophosphamide-Calicheamicin-Melphalan-Busulfan-Palifosfamide-Carmustine-RITA-SJG-136-Fotemustine-Lomustine-
生物活性
Description
Procarbazine Hcl, an antineoplastic chemotherapy drug, is an alkylating agent for the treatment of Hodgkin's lymphoma and certain brain cancers; also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine.Target: DNA alkylating agent; MAOThe mechanism of action is not fully understood. Metabolism yields azo-procarbazine and hydrogen peroxide which results in the breaking of DNA strands.Exposure to procarbazine hydrochloride by intraperitoneal injection caused tumors in rats and mice at several different tissue sites. In both rats and mice, it caused cancer of the brain (olfactory neuroblastoma) and hematopoietic system (lymphoma in rats and lymphoma or leukemia in mice). In rats, it also caused mammary-gland cancer (adenocarcinoma) in both sexes. In mice, it also caused benign lung tumors (adenoma) in both sexes and uterine cancer (adenocarcinoma) in females [1] [2].Procarbazine hydrochloride is an oral alkylating agent primarily used as a component of chemotherapy regimens for Hodgkin's lymphoma, as well as in regimens for primary central nervous system lymphoma and high-grade gliomas. After discontinuation of all drug therapy, exclusion of other potential etiologies, and resolution of hepatic injury, the patient was rechallenged with procarbazine and again experienced fever with aminotransferase level elevation [3].
Clinical Trial
Incheon St.Mary's Hospital-National Cancer Center, Korea
Recurrent Glioblastoma Multiforme
October 2012
Phase 2
M.D. Anderson Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Phase 3
Assistance Publique - Hôpitaux de Paris-French Innovative Leukemia Organisation
Lymphoma
July 2007
Phase 2
New Approaches to Brain Tumor Therapy Consortium-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
July 1999
Phase 1-Phase 2
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
January 2004
Phase 2
Memorial Sloan Kettering Cancer Center
CNS Lymphoma-CNS Brain Cancer-Non-Hodgkin's Lymphoma
December 2004
Phase 2
Pfizer
Brain and Central Nervous System Tumors
February 1998
Phase 3
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-NRG Oncology
Chemotherapeutic Agent Toxicity-Cognitive/Functional Effects-Lymphoma-Neurotoxicity-Radiation Toxicity
September 2011
Phase 2
OHSU Knight Cancer Institute-National Cancer Institute (NCI)
Lymphoma
January 2000
Phase 2
M.D. Anderson Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
February 1989
Phase 2
Newcastle-upon-Tyne Hospitals NHS Trust
Lymphoma
January 2004
Phase 2
Institute of Cancer Research, United Kingdom-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
October 2002
Phase 3
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
June 1998
Phase 2
Children's Oncology Group-National Cancer Institute (NCI)
Lymphoma
October 1999
Phase 2
Weill Medical College of Cornell University
Non-Hodgkin's Lymphoma
November 2004
Phase 2
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
July 1996
Phase 2
European Organisation for Research and Treatment of Cancer - EORTC-Medical Research Council
Brain and Central Nervous System Tumors
August 1996
Phase 3
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
July 1997
Phase 2
Indiana University-Indiana University Melvin and Bren Simon Cancer Center
Bone Marrow Suppression-Brain and Central Nervous System Tumors-Drug/Agent Toxicity by Tissue/Organ
February 2000
Phase 1
Eastern Cooperative Oncology Group
Lymphoma
December 2006
Phase 2
University Hospital Freiburg-Universitätsklinikum Köln-Ludwig-Maximilians - University of Munich-University Hospital Heidelberg-University Hospital Ulm
Primary Non Hodgkin Lymphoma of the Central Nervous System
September 2009
Phase 2
Hebei Yanda Hospital-Beijing Tiantan Hospital
Recurrent High-grade Glioma
February 2015
AIDS Malignancy Consortium-National Cancer Institute (NCI)-The EMMES Corporation
AIDS-related Diffuse Large Cell Lymphoma-AIDS-related Diffuse Mixed Cell Lymphoma-AIDS-related Diffuse Small Cleaved Cell Lymphoma-AIDS-related Immunoblastic Large Cell Lymphoma-AIDS-related Lymphoblastic Lymphoma-AIDS-related Peripheral/Systemic Lymphoma-AIDS-related Small Noncleaved Cell Lymphoma-Stage III AIDS-related Lymphoma-Stage IV AIDS-related Lymphoma
September 2016
Phase 2
Memorial Sloan Kettering Cancer Center-Northwestern Memorial Hospital-Columbia University-Kentuckiana Cancer Institute-University of Virginia-University of Vermont
Lymphoma
August 28, 2002
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
March 1998
Phase 2
Children's Cancer and Leukaemia Group-National Cancer Institute (NCI)
Lymphoma
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-North Central Cancer Treatment Group-Southwest Oncology Group-Eastern Cooperative Oncology Group-NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
July 1994
Phase 3
Radiation Therapy Oncology Group-National Cancer Institute (NCI)-Southwest Oncology Group-North Central Cancer Treatment Group-Eastern Cooperative Oncology Group-NRG Oncology
Brain and Central Nervous System Tumors
October 1998
Phase 2-Phase 3
Children's Oncology Group-National Cancer Institute (NCI)
Brain Tumors-Central Nervous System Tumors
April 1997
Phase 3
Harlachinger Krebshilfe e.V.-Deutsche AIDS Gesellschaft e.V.
HIV-associated Hodgkin Lymphoma
March 2004
Phase 2
Christine Mauz-Körholz-Deutsche Krebshilfe e.V., Bonn (Germany)-Euronet Worldwide-Martin-Luther-Universität Halle-Wittenberg
Lymphoma
January 2007
Phase 3
Fondazione Michelangelo
Hodgkin Lymphoma
March 2000
Phase 3
Northwestern University-Pharmacyclics LLC.
Brain and Central Nervous System Tumors-Lymphoma-Neurotoxicity
November 2008
Early Phase 1
The Lymphoma Academic Research Organisation
Hodgkin Lymphoma
April 2015
Phase 2
M.D. Anderson Cancer Center-Genentech, Inc.
Lymphoma
March 1998
Phase 3
University of Cologne
Hodgkin Lymphoma
October 2012
Phase 2
University College, London
Lymphoma-Neurotoxicity
March 2008
Phase 2
University of Cologne
Classical Hodgkin Lymphoma
July 2016
Phase 3
Cancer Research UK-National Cancer Institute (NCI)
Lymphoma
August 2008
Phase 3
University of Cologne
Hodgkin Lymphoma
December 2011
Phase 3
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Lymphoma
July 1997
Phase 2
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)-European Organisation for Research and Treatment Center (EORTC)-NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
September 2009
Phase 3
St. Jude Children's Research Hospital-Children's Hospital of Philadelphia-National Cancer Institute (NCI)
Ataxia-Telangiectasia
September 2002
Colorado Health Foundation-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
April 1998
Phase 3
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
August 1997
Phase 2
